ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

VP Clinical Development and Global Program Lead (GPL) for GI Cancers at Erasca - ApplyBlast

VP Clinical Development and Global Program Lead (GPL) for GI Cancers

Erasca

1 month ago

South San Francisco, California, United States

Hybrid

Full Time

Executive

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

The VP Clinical Development and Global Program Lead (GPL) for GI Cancers provides medical leadership and oversight for pancreatic and colorectal cancer development programs at a clinical-stage precision oncology company. This role involves driving clinical development strategy, protocol design, and registrational execution while serving as a hands-on clinical lead and medical monitor. The position requires collaboration with the Chief Medical Officer and cross-functional teams to advance the company's mission of erasing cancer.

Responsibilities

Lead clinical development strategy and execution for pancreatic and colorectal cancer programs
Design and implement clinical trials and author regulatory documents for INDs and NDAs
Mentor medical directors and clinical scientists while managing cross-functional program teams

Skills

Qualifications

M.D. degreeOncology fellowship trainingBoard certification or eligibility in Oncology or Oncology/Hematology

About Erasca

erasca.com

Headquarters

San Diego, California, United States

Company Size

51-200 employees

Founded

2018

View Profile

Erasca is a clinical-stage precision oncology company on a mission “to erase cancer,” focused on therapies that shut down the RAS/MAPK signaling cascade — one of the most commonly mutated cancer pathways. Its pipeline comprises targeted programs that attack the RAS/MAPK pathway at multiple nodes, with the goal of addressing cancers driven by these mutations (a pathway that affects roughly 5.5 million people worldwide each year). By developing precision small molecules and combination strategies, Erasca aims to deliver transformative treatments that improve outcomes across a broad range of devastating cancers.